LivaNova (NASDAQ:LIVN) Raised to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research report report published on Tuesday morning.

A number of other research analysts have also recently issued reports on the stock. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Down 0.4 %

Shares of NASDAQ LIVN opened at $49.94 on Tuesday. The stock has a market capitalization of $2.71 billion, a PE ratio of 118.90 and a beta of 0.98. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $51.88 and its two-hundred day simple moving average is $51.27. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in shares of LivaNova by 2.0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after acquiring an additional 299 shares in the last quarter. Atria Investments Inc lifted its position in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares in the last quarter. Fifth Third Bancorp increased its stake in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the period. State of Alaska Department of Revenue raised its holdings in LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after acquiring an additional 425 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in LivaNova by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after acquiring an additional 659 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.